Keywords JYNNEOS

Monkeypox Update: FDA Authorizes Emergency Use of JYNNEOS Vaccine to Increase Vaccine Supply

FDA

For individuals 18 years of age and older determined to be at high risk of monkeypox infection, the EUA now allows for a fraction of the JYNNEOS dose to be administered between the layers of the skin (intradermally).

keywords: JYNNEOS, Monkeypox, poxvirus, vaccines

Key Facts About Monkeypox Vaccine

FDA

JYNNEOS is the only FDA-licensed vaccine in the United States to prevent monkeypox disease in individuals 18 years of age and older.

keywords: JYNNEOS, Monkeypox, vaccines

Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

CDC/MMWR

27 May 2022

Rao AK, Petersen BW, Whitehill F, et al.

keywords: JYNNEOS, Monkeypox, poxvirus, vaccination

Resources with keywords: JYNNEOS